Maiwald Patent Und Rechtsanwaltsgesellschaft competitive analysis

Explore patent oppositions filed by Maiwald Patent Und Rechtsanwaltsgesellschaft against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jun 25, 2026
Patent NumberTitleApplicantOpposition Date
Treatment Of Age Related Macular Degeneration With A Small Active Choroidal Neovascularization LesionBAYER HEALTHCAREOct 5, 2022
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMODERNASep 1, 2022
In Vitro Glycoengineering Of AntibodiesF HOFFMANN LA ROCHEAug 17, 2022
Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal CancerBRISTOL MYERS SQUIBBJul 26, 2022
Adeno-Associated For Therapeutic Delivery To Central Nervous SystemBELURJul 13, 2022
Method For Regulating A Heating Device For Heating A Fluid For A Dialysis Liquid Circuit, Control Device, And Blood Treatment DeviceFRESENIUS MEDICAL CARE DEUTSCHLANDJun 7, 2022
High-Density Cell Banking MethodsGENZYMEJun 1, 2022
Compositions Comprising Synthetic Polynucleotides Encoding Crispr Related Proteins And Synthetic Sgrnas And Methods Of UseMODERNAMay 25, 2022
Formulations Of EnzalutamideASTELLAS PHARMAMay 18, 2022
Medical Device Containing A Cake Composition Comprising Aripiprazole As An Active Ingredient, And A Cake Composition Comprising Aripiprazole As An Active IngredientOTSUKA PHARMACEUTICALApr 27, 2022

Latest PTAB cases involving Maiwald Patent Und Rechtsanwaltsgesellschaft

Discover the latest PTAB cases involving Maiwald Patent Und Rechtsanwaltsgesellschaft, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Maiwald Patent Und Rechtsanwaltsgesellschaft with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jun 25, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MAIWALD PATENT UND RECHTSANWALTSGESELLSCHAFT54 - - -
F HOFFMANN LA ROCHE16197 - -
GENENTECH - 122 - 66
OTSUKA PHARMACEUTICAL - 31 - 1